Literature DB >> 2407300

Chronic myeloid leukemia may be associated with several bcr-abl transcripts including the acute lymphoid leukemia-type 7 kb transcript.

L Selleri1, M von Lindern, A Hermans, D Meijer, G Torelli, G Grosveld.   

Abstract

In the majority of Philadelphia (Ph)-positive chronic myeloid leukemia (CML) patients, the c-abl gene is fused to the bcr gene, resulting in the transcription of an 8.5 kb chimeric bcr-abl mRNA, which is translated into a p210bcr-abl fusion protein. In about 50% of the Ph-positive acute lymphoid leukemias (ALL), the bcr-abl gene fusion is identical to CML, while in 50% an alternative fusion between these two genes occurs, in which the central bcr-sequences are absent. This results in transcription of a 7 kb bcr-abl mRNA, encoding a P190bcr-abl fusion protein. Cloning and sequencing of the chimeric part of bcr-abl cDNAs from two Ph-positive CML patients in chronic phase showed that in one patient, as in the Ph-positive ALL, all central bcr sequences are absent, while in the other patient, part of the bcr central sequences are deleted. Therefore, we speculate that the presence of the 7 kb chimeric ALL type mRNA in one of the patients is not sufficient to drive an acute rather than a chronic leukemic process in this case. The deletions of the central bcr-sequences described here define the minimal sequence requirement of the bcr-abl fusion gene in CML patients so far.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2407300

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

1.  Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance.

Authors:  Dushyant Verma; Hagop M Kantarjian; Dan Jones; Rajyalakshmi Luthra; Gautam Borthakur; Srdan Verstovsek; Mary Beth Rios; Jorge Cortes
Journal:  Blood       Date:  2009-06-16       Impact factor: 22.113

2.  Chronic myeloid leukemia presenting ALL-type BCR/ABL transcript.

Authors:  Y Kunieda; M Okabe; M Kurosawa; T Itaya; M Kakinuma; T Miyazaki
Journal:  Ann Hematol       Date:  1994-10       Impact factor: 3.673

3.  Differences in oncogenic potency but not target cell specificity distinguish the two forms of the BCR/ABL oncogene.

Authors:  M Kelliher; A Knott; J McLaughlin; O N Witte; N Rosenberg
Journal:  Mol Cell Biol       Date:  1991-09       Impact factor: 4.272

4.  Analysis of the clinico-hematological relevance of the breakpoint location within M-BCR in chronic myeloid leukemia.

Authors:  Ayda Bennour; Ines Ouahchi; Bechir Achour; Monia Zaier; Yosra Ben Youssef; Abderrahim Khelif; Ali Saad; Halima Sennana
Journal:  Med Oncol       Date:  2012-12-27       Impact factor: 3.064

5.  Genetic analysis of p53 and RB1 tumor-suppressor genes in blast crisis of chronic myeloid leukemia.

Authors:  G Gaidano; A Serra; A Guerrasio; G Rege-Cambrin; U Mazza; G Saglio
Journal:  Ann Hematol       Date:  1994-01       Impact factor: 3.673

6.  Molecular localization of the t(11;22)(q24;q12) translocation of Ewing sarcoma by chromosomal in situ suppression hybridization.

Authors:  L Selleri; G G Hermanson; J H Eubanks; K A Lewis; G A Evans
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-01       Impact factor: 11.205

7.  Frequencies of BCR-ABL1 fusion transcripts among Sudanese chronic myeloid leukaemia patients.

Authors:  Emad-Aldin I Osman; Kamal Hamad; Imad M Fadl Elmula; Muntaser E Ibrahim
Journal:  Genet Mol Biol       Date:  2010-06-01       Impact factor: 1.771

8.  The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.

Authors:  S Li; R L Ilaria; R P Million; G Q Daley; R A Van Etten
Journal:  J Exp Med       Date:  1999-05-03       Impact factor: 14.307

9.  A case of chronic myeloid leukemia with the m-bcr (p190) molecular rearrangement identified during treatment.

Authors:  Mariana Beatriz Asinari; Maximiliano Zeballos; Sturich Alicia; Brenda Nidia Ricchi; Ana Lisa Basquiera
Journal:  Rev Bras Hematol Hemoter       Date:  2014-11-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.